Medical/Pharmaceuticals
2024 ESMO Asia: TransThera announces clinical data of tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma (BTC)
NANJING, China and GAITHERSBURG, Md., Dec. 9, 2024 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of tinengotinib in combination with atezol...
2024-12-09 23:00
1655
Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW
Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer d...
2024-12-09 22:00
1570
WAT Medical Sponsors American Headache Society 2024 Scottsdale Headache Symposium
VANCOUVER, BC, Dec. 9, 2024 /PRNewswire/ -- WAT Medical Enterprise proudly sponsored the 2024 Scottsdale Headache Symposium, organized by the American Headache Society fromNovember 14-17 in Scottsdale, AZ. This annual event brought together a multidisciplinary audience of neurologists, general p...
2024-12-09 22:00
930
Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial
* Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 * Appoints US-based Chief Commercial Officer, Andrew Udell * Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- A...
2024-12-09 21:00
1522
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
BEIJING, Dec. 9, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that the National Medical Products Administration of...
2024-12-09 20:30
1546
Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting
DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment o...
2024-12-09 18:00
1109
Dr. James G. Fujimoto of U.S. Awarded 45th Honda Prize for His Team's Development of Optical Coherence Tomography (OCT): Real-time Tissue Imaging Technology
- OCT Marks Breakthrough in Disease Detection and Manufacturing - TOKYO, Dec. 9, 2024 /PRNewswire/ -- The Honda Foundation in Tokyo held the 45th Honda Prize Award Ceremony onNovember 18, 2024, where this year's prize was awarded to Dr.James G. Fujimoto, Elihu Thomson Professor of Electrical Eng...
2024-12-09 16:00
1148
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...
2024-12-09 10:40
1191
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...
2024-12-09 08:42
1028
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, two prestigious benchmarks jointly compiled by FTSE Russell and the Taiwan S...
2024-12-07 08:57
3217
Another star technology platform of the Sanyou AI-STAL family
——Introducing Sanyou Mrna Mab innovative antibody generation technology platform SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes h...
2024-12-06 18:30
1580
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...
2024-12-06 07:56
1252
Lunit and Volpara Unveiled Unified Ecosystem at RSNA 2024 to Transform Global Cancer Care
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- At this year's RSNA 2024 Annual Meeting, Lunit (KRX:328130.KQ),...
2024-12-05 22:07
1658
Neurophet to Participate in RSNA 2024: Unveiling Multiple Sclerosis Analysis Technology with Neurophet AQUA
* Demonstrates MS Analysis Technology, Recently Secured FDA 510(k) Clearance * Introduces 'Neurophet AQUA AD,' a Total Solution for Alzheimer's Disease Treatment Prescription, at the AI Theater SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution...
2024-12-05 22:00
1508
Rhein Laser Announces FDA 510(k) Clearance of UroFiber 60Q
The Most Powerful Thulium SuperPulsed Fiber Laser for Urology is Here WUHAN, China, Dec. 4, 2024 /PRNewswire/ -- Rhein Laser Technologies Co., Ltd. is proud to announce that its UroFiber® 60Q SuperPulsed Thulium Fiber Laser System received FDA 510(k) clearance (K242293) onNovember 19, 2024, marki...
2024-12-04 22:00
1385
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been approved for marketing by the National Medical Products Admini...
2024-12-04 18:10
1510
Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective, open-label, single-arm, multi-center phase Ib/II clinical study (AK104-IIT-018) of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced or metastat...
2024-12-04 13:09
1384
Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusi...
2024-12-04 08:30
1146
VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery
* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery * Statistically and clinically meaningful reductions in inflammation and ...
2024-12-04 00:00
1651
Terumo Interventional Systems Announces Launch of Its R2P NaviCross Peripheral Support Catheter
– Provides interventionalists with optimal product choices for more complex radial-to-peripheral procedures– SOMERSET, N.J., Dec. 3, 2024 /PRNewswire/ -- Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the launch and commercial availability of its R2...
2024-12-03 21:00
876
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 313 media titles]
2024-12-27 13:17
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 270 media titles]
2024-12-30 15:33
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 254 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 249 media titles]
2024-12-25 15:45Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
[Picked up by 242 media titles]
2024-12-27 11:24
Most Read
/C O R R E C T I O N -- Ellington Properties/
2024-12-27 20:57
9030
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
2024-12-27 13:17
8072
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
2024-12-24 00:06
7802
Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
2024-12-27 11:24
7101